Obstructive sleep apnoea and atrial fibrillation ablation outcomes

Obstructive sleep apnoea (OSA) is common among people with atrial fibrillation (AF), yet it can remain undiagnosed until recurrent episodes, difficult rate control or an unsuccessful ablation prompts a broader assessment. Repeated upper-airway obstruction during sleep produces intermittent hypoxaemia, sympathetic surges and large swings in intrathoracic pressure. These effects can promote atrial electrical instability and structural remodelling, creating a biological environment in which AF is more likely to persist.

For clinicians and researchers, the key issue is practical as well as mechanistic: how much does untreated sleep-disordered breathing influence catheter ablation success, and can effective OSA management improve long-term rhythm outcomes? The answer is clinically relevant in Australia, where pathways through general practice, public hospitals, private electrophysiology services and sleep clinics vary considerably between metropolitan and regional communities.

Why sleep apnoea changes the atrial substrate

During an obstructive event, the airway narrows or closes while respiratory effort continues. Oxygen levels fall, carbon dioxide rises and intrathoracic pressure becomes markedly negative. The resulting sympathetic activation may trigger premature atrial contractions, while pressure loading and inflammation can contribute to atrial dilatation and fibrosis. Over time, these changes increase conduction heterogeneity and shorten the margin for maintaining sinus rhythm.

OSA also commonly travels with hypertension, obesity, diabetes, heart failure and metabolic disease. These comorbidities independently affect AF progression and ablation outcomes, making it difficult to isolate the effect of apnoea in observational studies. A patient with persistent AF and severe OSA may therefore carry several interacting risk factors rather than a single reversible cause.

The relationship is bidirectional. AF can worsen sleep quality through nocturnal symptoms, medication effects and haemodynamic disturbance, while fragmented sleep and untreated apnoea may increase atrial arrhythmia burden. This is why an AF review should consider sleep symptoms even when the patient does not report obvious daytime sleepiness. Bed-partner observations of loud snoring, witnessed pauses or gasping may be more informative than the patient’s own impression.

What the evidence says about ablation success

Studies consistently report a higher prevalence of OSA in patients referred for AF ablation than in the general population. Untreated or inadequately treated OSA has been associated with a greater risk of AF recurrence after pulmonary vein isolation, particularly when other risk factors remain uncontrolled. Recurrence may present as paroxysmal AF, atrial flutter, atrial tachycardia or a need for repeat cardioversion and repeat ablation.

The evidence supporting continuous positive airway pressure (CPAP) is encouraging but not uniform. Some cohorts show substantially lower recurrence rates among patients who use CPAP regularly, while other studies find a smaller or statistically uncertain benefit after adjustment for body weight, hypertension, AF type and treatment adherence. Differences in diagnostic methods, monitoring intensity and definitions of CPAP use explain part of this variation.

Ablation itself should therefore not be viewed as a substitute for managing sleep-disordered breathing. Pulmonary vein isolation can reduce the arrhythmic trigger burden, but it does not remove the nocturnal pressure changes or autonomic stress caused by OSA. A person who feels well after ablation may still have clinically important apnoea, especially if rhythm monitoring is intermittent and symptoms are subtle.

For Australian patients, access can shape this sequence of care. A metropolitan patient may move from a GP referral to a private sleep physician and electrophysiologist relatively quickly, whereas someone in regional New South Wales, Queensland or Western Australia may face longer travel and waiting times. Home sleep testing can improve convenience, but the choice between a home study and laboratory polysomnography should reflect clinical complexity rather than geography alone.

Finding and treating OSA before ablation

Screening questionnaires such as STOP-BANG can identify increased risk, but they do not establish the diagnosis. High-risk patients generally need objective testing, with home sleep apnoea testing suitable for many adults and in-laboratory polysomnography useful when there is suspected central sleep apnoea, significant cardiopulmonary disease, neuromuscular weakness or an unexplained mismatch between symptoms and initial results.

Timing matters. Screening before ablation allows the treatment plan to address modifiable risk factors alongside anticoagulation, blood pressure, alcohol intake, weight and glycaemic control. Severe OSA, prominent nocturnal desaturation or marked daytime sleepiness may justify prioritising sleep treatment before the procedure, particularly when the patient’s AF is stable enough to permit that approach.

CPAP remains the standard treatment for moderate to severe OSA when tolerated. Its potential value after AF ablation depends heavily on consistent use, correct mask fit and follow-up of residual events. Mandibular advancement devices may be appropriate for selected patients with mild to moderate OSA or CPAP intolerance, while positional therapy, weight management and avoidance of sedatives or excess alcohol can support the broader strategy.

Communication should be straightforward and culturally safe. In Australia, some patients describe CPAP as “a bit of a rig” or worry that it will interfere with travel, shift work or life on the road. Demonstrating different masks, arranging early review and explaining the connection between nightly treatment and rhythm control can improve engagement. Aboriginal and Torres Strait Islander patients may face additional barriers linked to distance, cost, housing, access to specialist services and culturally safe care; these factors need to be addressed rather than interpreted as poor motivation.

Integrating sleep care with electrophysiology

A comprehensive AF pathway should record OSA status, severity, treatment, adherence and residual symptoms alongside rhythm data. The electrophysiology team can coordinate with sleep physicians, respiratory specialists, cardiologists, GPs and allied health professionals. This shared model is especially useful when a patient has obesity, resistant hypertension, heart failure with preserved ejection fraction or recurrent arrhythmia after apparently successful pulmonary vein isolation.

Procedural planning may also be affected. OSA can increase the risk of peri-procedural airway obstruction and oxygen desaturation under sedation or general anaesthesia. Anaesthetic assessment, postoperative monitoring and a plan for the patient’s usual positive-airway-pressure device are important. These considerations do not necessarily delay ablation, but they support safer workflow and clearer discharge instructions.

Risk-factor modification should continue after the blanking period. A reduction in AF episodes during the first few months does not prove that OSA has been controlled, and recurrence later may reflect progressive atrial remodelling rather than an isolated procedural failure. Wearable devices, extended ambulatory monitoring and implantable loop recorders can reveal asymptomatic episodes that would otherwise be missed.

The wider rhythm field also illustrates why procedural evidence must be interpreted in context. Work on conduction-system pacing, including this report of early pacing results, shows how changes in cardiac activation and device strategy may influence outcomes in selected patients. For AF ablation, the parallel lesson is that the procedure forms one part of a long-term rhythm-care system, alongside sleep, ventricular function, blood pressure and lifestyle management.

Priorities for research and clinical practice

Future studies need stronger designs to determine whether treating OSA directly improves ablation outcomes. Randomised trials should use objective sleep testing, verified CPAP adherence and continuous or extended rhythm monitoring. They should also distinguish obstructive from central sleep apnoea and report clinically meaningful outcomes such as AF burden, repeat ablation, hospitalisation, stroke and quality of life.

Research should account for Australia’s diverse health system. Public and private care pathways may produce different waiting times, access to sleep studies and follow-up patterns. Rural and remote programmes could evaluate telehealth review, local diagnostic testing and culturally appropriate education. Cost-effectiveness analyses should include travel, equipment, lost work and the potential reduction in emergency presentations or repeat procedures.

Clinical teams can act on current evidence without waiting for every uncertainty to disappear. Patients referred for AF ablation should be assessed for snoring, witnessed apnoeas, nocturia, morning headaches, resistant hypertension, obesity and daytime fatigue. Those at elevated risk should receive objective testing, while diagnosed patients should be offered practical support for CPAP or an appropriate alternative.

For authors and investigators developing this evidence base, the Journal of Arrhythmia provides submission guidance for original research, reviews and clinically relevant work in electrophysiology. Clear reporting of OSA definitions, treatment adherence, ablation technique, rhythm monitoring and follow-up duration will help clinicians judge whether findings apply to their own patients.

Atrial fibrillation ablation should be approached as part of comprehensive risk-factor care rather than a standalone intervention. Screen for sleep-disordered breathing, treat confirmed OSA, monitor adherence and coordinate follow-up across primary care, sleep medicine and electrophysiology. Clinicians, researchers and trainees can explore the Journal of Arrhythmia’s evidence and contribute well-designed Australian data to improve rhythm outcomes for patients living with both AF and OSA.